WASHINGTON (CN) - The Defense Department plans to add TRICARE insurance coverage for some National Cancer Institute's Phase I studies for certain beneficiaries, and requests public comment.
The coverage would be only for those trials "with clinical or preclinical data providing a reasonable expectation that the treatment will be at least as effective as the non-investigational alternative." The patients it would cover would be those "for whom standard treatment has been or would be ineffective, does not exist, or there is no superior non-investigational treatment alternative."
Phase I trials are the first clinical treatment trials conducted on people. The studies evaluate how a new drug should be given (by mouth, injected into the blood, or injected into the muscle), how often, and what dose is safe.
Subscribe to Closing Arguments
Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.